Meridian, a subsidiary of Pfizer that manufactures EpiPen auto-injectors, has experienced intermittent constraints affecting U.S. supply. The U.S. Food and Drug Administration (FDA) has posted a supply notification on its website about EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths, to provide greater transparency and confirm that the product remains available.

Pfizer takes very seriously the importance of EpiPen to everyone who needs it, and we are working tirelessly to increase production as rapidly as possible. We are currently shipping EpiPen, with production increasing over the last few months and anticipated to continue to increase and stabilize over the coming months.

Because EpiPen is distributed and sold by Mylan Specialty L.P., medical professionals should direct questions about EpiPen usage to Mylan at 800-796-9526.

Pfizer is committed to open communication and will continue to provide updates on this website as we have them.

ADDITIONAL INFORMATION FOR PATIENTS

Please be assured that your health and safety are our highest priorities, and that we continually strive to ensure the safety, quality and efficacy of the EpiPen products we make.

If you have supplies of unexpired EpiPen in quantities deemed medically appropriate by your doctor, we urge prudence in refilling additional prescriptions for any dosage of EpiPen during this temporary period of manufacturing constraints, in order to help ensure that other patients have access to this medication.